ResMed (ASX: RMD) is a global medical technology company focused on diagnosing and treating sleep disorders, particularly obstructive sleep apnoea, along with other respiratory conditions. The company is best known for its continuous positive airway pressure (CPAP) devices, masks and connected digital health platforms that help patients manage therapy at home, while also providing software for residential and aged care providers.

Its strategy increasingly combines hardware devices with cloud-connected software and data analytics, allowing clinicians and patients to monitor treatment and outcomes remotely across more than 100 countries. Strong global demand for sleep and breathing health devices and its growing digital health ecosystem have been key drivers of recent performance and positioning in healthcare technology.

The company delivered strong full-year fiscal 2025 results, with revenue rising about 10% to roughly US$5.1 billion and operating profit rising sharply (around 28%), supported by improved margins and strong demand across devices, masks and software segments.

ResMed is often considered one of the leading healthcare stocks on the ASX because it combines structural healthcare demand with strong profitability and recurring revenue characteristics. Sleep apnoea remains significantly under-diagnosed globally, creating long-term growth potential, while digital monitoring and software subscriptions add higher-margin recurring revenue streams. The company also benefits from rising awareness of sleep health, broader healthcare digitisation, and innovation in connected care platforms, all of which support sustained earnings growth and strong cash flow.

Dimerix is an emerging Australian biotechnology company focused on addressing unmet medical needs, primarily in the areas of kidney diseases and respiratory conditions. The company’s leading drug candidate, DMX-200, is being developed for FSGS, a kidney condition that affects millions globally.

The company is well poised, being in the middle of a Phase 3 trial which is expected to be the pivotal trial for regulatory approval and having 4 licensing deals worth a cumulative $1.4bn between them all, not accounting for future sales royalties. Dimerix's hope is that it can get regulatory approval prior to the formal end of the trial if the data is positive enough. On what basis? The FDA accepting 2 years' proteinuria as a sole endpoint - which Dimerix will very soon have.

For investors, Dimerix offers a lower-risk proposition given how advanced DMX-200 is, with substantial upside potential should its treatments achieve regulatory approval. The stock is well-suited for investors with a higher risk tolerance who are looking for opportunities in the rapidly advancing biotech industry. However, the potential volatility and unpredictability of clinical trial results are factors to consider before making an investment decision. With promising drug candidates and a growing research pipeline, Dimerix is one to watch in the biotech space.

Cochlear is a globally recognised leader in implantable hearing solutions, offering advanced cochlear implants that have transformed the lives of individuals with severe hearing loss. The company’s products, which include the Nucleus cochlear implant system, provide a life-changing alternative to traditional hearing aids for people with profound hearing loss.

The company operates in more than 100 countries and has implanted over 600,000 devices worldwide. In FY25, it made A$2.36bn in sales and an underlying profit of $392m. Cochlear continues to innovate, developing new technologies and enhancing the effectiveness of its implants.

The company’s robust revenue model is supported not only by the sale of implants but also by ongoing maintenance services and accessories. Cochlear’s long-standing commitment to research and development ensures its competitive edge in the market.

For investors, the company offers stability, with a proven track record of strong earnings growth and a commitment to shareholder value through dividends and share buybacks. Cochlear is well-positioned to benefit from the increasing demand for hearing solutions globally, particularly as the ageing population grows. For those looking for a dependable and innovative healthcare investment, Cochlear represents an attractive opportunity.